Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
axatilimab
- Development stage
- Approved
- Lead developer
- Syndax Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Axatilimab is a humanized IgG4 monoclonal antibody that targets the macrophage colony-stimulating factor 1 receptor (CSF-1R) on monocytes and macrophages. By inhibiting CSF-1R, it reduces the levels of pro-inflammatory and pro-fibrotic monocytes and macrophages, thereby addressing both inflammation and fibrosis in chronic graft-versus-host disease (cGVHD). Axatilimab is indicated for adults and pediatric patients weighing at least 40 kg who have failed at least two prior lines of systemic therapy for cGVHD. It is administered as an intravenous infusion. The drug was developed by Syndax Pharmaceuticals, which licensed global rights from UCB. Axatilimab was approved in the United States in August 2024 under the brand name Niktimvo[2][3][5][6][7].
- Brand names
- Niktimvo
- Other names
- axatilimab-csfr
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on axatilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on axatilimab.